1-(Bromomethyl)-4-(1,1-dimethylethyl)benzene → 1-(4-t-Butylbenzyl)-4,4-dimethyl-2-(adamantan-2-yl)-1,2-diazetidin-3-one
Reaction equation
[CH:1]12[CH2:10][CH:5]3[CH2:6][CH:7]([CH2:9][CH:3]([CH2:4]3)[CH:2]1[N:11]1[C:14](=[O:15])[C:13]([CH3:17])([CH3:16])[NH:12]1)[CH2:8]2.[C:18]([C:22]1[CH:29]=[CH:28][C:25]([CH2:26]Br)=[CH:24][CH:23]=1)([CH3:21])([CH3:20])[CH3:19]>>[C:18]([C:22]1[CH:23]=[CH:24][C:25]([CH2:26][N:12]2[C:13]([CH3:17])([CH3:16])[C:14](=[O:15])[N:11]2[CH:2]2[CH:3]3[CH2:4][CH:5]4[CH2:6][CH:7]([CH2:8][CH:1]2[CH2:10]4)[CH2:9]3)=[CH:28][CH:29]=1)([CH3:21])([CH3:19])[CH3:20]Participants
3
Procedure
2-(Adamantan-2-yl)-4,4-dimethyl-1,2-diazetidin-3-one and 4-t-butylbenzyl bromide were used for a similar reaction and treatment as Process 6 of Example 1, and the title compound was obtained as a white crystalline powder.
Sources & evidence
- ORD record
- ord-747021c21fcd442cafa86b2a53ab99c9
- Source dataset
- uspto-grants-2012_08
- Patent number
- US08252781B2
Reaction notes
Loading…